Urothelial carcinoma
Urothelial · Oncology · 2 drugs · 4 indications
Competitive Landscape (2 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Trodelvy | GILD | TROP2-directed (SN-38 payload) | ADC | IV | APPROVED |
| Padcev | ALPMY | Nectin-4-directed (MMAE payload) | ADC | IV | APPROVED |
Indications (4)
Locally advanced/metastatic UC 1L
Locally advanced/metastatic UC 2L+
Muscle-invasive bladder cancer perioperative
Upcoming Catalysts
PADCEV + Keytruda - MIBC - Japan sNDA FiledREGULATORY
ALPMYJan 30, 2026
Trodelvy - 1L NSCLC - Ph3 - Topline (EVOKE-03)CLINICAL
GILDQ2 2026
PADCEV + Keytruda - Cis-Ineligible MIBC - EMA ApprovalREGULATORY
ALPMY2026
Trodelvy - 1L mTNBC - FDA ApprovalREGULATORY
GILDH1 2026
Trodelvy - 1L HR+/HER2- mBC - Ph3 - OS Data (ASCENT-07)CLINICAL
GILD2026
Trodelvy - 1L mTNBC (non-CPI) - FDA Approval (ASCENT-03)REGULATORY
GILDH2 2026
Trodelvy + Keytruda - 1L PD-L1+ mTNBC - FDA Approval (ASCENT-04)REGULATORY
GILDH2 2026
Data from Supabase · Updated 2026-03-24